Biofield Petitions for Less Burdensome Route For Breast Cancer Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
Biofield Corp. expects to hear from FDA within 60 days regarding a de novo petition for reclassification of its investigational breast cancer diagnostic device to Class II status